To evaluate the anti-tumor effect of simultaneous inhibition of PI3Kβ/δ and mTOR in vivo, we co-administrated AZD8186 and AZD2014 in an ABC (OCI-Ly10) and a GCB (K422) DLBCL xenograft mouse model. Here, MTOR is linked to diffuse large B-cell lymphoma.